Snyder LA - Search Results

1

Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.

Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL. Dean NR, et al. Among authors: snyder la. Clin Cancer Res. 2009 Jun 15;15(12):4058-65. doi: 10.1158/1078-0432.CCR-09-0212. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509148 Free PMC article.

2

Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway.

Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, Cunningham M, Snyder LA, Bugelski P, Yan L. Tang Y, et al. Among authors: snyder la. Mol Cancer Res. 2006 Jun;4(6):371-7. doi: 10.1158/1541-7786.MCR-06-0042. Mol Cancer Res. 2006. PMID: 16778084

3

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Loberg RD, et al. Among authors: snyder la. Cancer Res. 2007 Oct 1;67(19):9417-24. doi: 10.1158/0008-5472.CAN-07-1286. Cancer Res. 2007. PMID: 17909051

4

A review of antibody therapeutics and antibody-related technologies for oncology.

Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, Nakada MT. Scallon BJ, et al. Among authors: snyder la. J Immunother. 2006 Jul-Aug;29(4):351-64. doi: 10.1097/01.cji.0000199196.97845.c3. J Immunother. 2006. PMID: 16799330 Review. No abstract available.

5

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. Loberg RD, et al. Among authors: snyder la. Neoplasia. 2007 Jul;9(7):556-62. doi: 10.1593/neo.07307. Neoplasia. 2007. PMID: 17710158 Free PMC article.

6

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. Li X, et al. Among authors: snyder la. Cancer Res. 2009 Feb 15;69(4):1685-92. doi: 10.1158/0008-5472.CAN-08-2164. Epub 2009 Jan 27. Cancer Res. 2009. PMID: 19176388 Free PMC article.

7

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

Zhu X, Fujita M, Snyder LA, Okada H. Zhu X, et al. Among authors: snyder la. J Neurooncol. 2011 Aug;104(1):83-92. doi: 10.1007/s11060-010-0473-5. Epub 2010 Nov 30. J Neurooncol. 2011. PMID: 21116835 Free PMC article.

8

CCL2 blockade augments cancer immunotherapy.

Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM. Fridlender ZG, et al. Among authors: snyder la. Cancer Res. 2010 Jan 1;70(1):109-18. doi: 10.1158/0008-5472.CAN-09-2326. Epub 2009 Dec 22. Cancer Res. 2010. PMID: 20028856 Free PMC article.

9

Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.

Tsui P, Das A, Whitaker B, Tornetta M, Stowell N, Kesavan P, Kaiser E, Lacy ER, Yan L, Snyder LA, Sweet R. Tsui P, et al. Among authors: snyder la. Hum Antibodies. 2007;16(3-4):117-25. Hum Antibodies. 2007. PMID: 18334747

10

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.

Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, Eber MR, Soki FN, Sadler D, Sud S, Tisdelle S, Daignault SD, Nemeth JA, Snyder LA, Wronski TJ, Pienta KJ, McCauley LK. Park SI, et al. Among authors: snyder la. Cancer Res. 2012 May 15;72(10):2522-32. doi: 10.1158/0008-5472.CAN-11-2928. Cancer Res. 2012. PMID: 22589273 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page